Abstract
Amyloid beta (Aβ) protein is the key component of amyloid plaques in Alzheimers disease brain whereas stefin B is an intracellular cysteine proteinase inhibitor, broadly distributed in different tissue and recently reported to form amyloid fibrils in vitro. By reducing the pH to 4.6, the native conformation of both polypeptides are changed into less ordered metastable intermediates that are stabilized by formation of the more stable fibrils. In Aβ, the Glu at position 11 was found to be responsible for the conformational change at pH 4.6. Metal ions, including copper and zinc, could also induce conformational changes of Aβ at neutral pH. The acid modified Aβ conformer exhibited protease K resistance, preferential internalization and accumulation in the human glial cells. In stefin B, reducing the pH to pH 3.3 results in another intermediate of the moltenglobule type which also leads to amyloid fibril formation. Multiple sequence alignment revealed distinct similarities of Aβ (1-42) peptide, stefin B (13 to 61 residues) and prion fragment (90 to 144 residues).
Keywords: Amyloid, metal ions, protease resistance, stefin B, cystatins, molten globule, amyloidfibrillogenesis
Current Medicinal Chemistry
Title: Conformational Changes Preceding Amyloid-fibril Formation of Amyloid-beta and Stefin B; Parallels in pH Dependence
Volume: 9 Issue: 19
Author(s): Yoichi Matsunaga, Eva Zerovnik, Tatsuo Yamada and Vito Turk
Affiliation:
Keywords: Amyloid, metal ions, protease resistance, stefin B, cystatins, molten globule, amyloidfibrillogenesis
Abstract: Amyloid beta (Aβ) protein is the key component of amyloid plaques in Alzheimers disease brain whereas stefin B is an intracellular cysteine proteinase inhibitor, broadly distributed in different tissue and recently reported to form amyloid fibrils in vitro. By reducing the pH to 4.6, the native conformation of both polypeptides are changed into less ordered metastable intermediates that are stabilized by formation of the more stable fibrils. In Aβ, the Glu at position 11 was found to be responsible for the conformational change at pH 4.6. Metal ions, including copper and zinc, could also induce conformational changes of Aβ at neutral pH. The acid modified Aβ conformer exhibited protease K resistance, preferential internalization and accumulation in the human glial cells. In stefin B, reducing the pH to pH 3.3 results in another intermediate of the moltenglobule type which also leads to amyloid fibril formation. Multiple sequence alignment revealed distinct similarities of Aβ (1-42) peptide, stefin B (13 to 61 residues) and prion fragment (90 to 144 residues).
Export Options
About this article
Cite this article as:
Matsunaga Yoichi, Zerovnik Eva, Yamada Tatsuo and Turk Vito, Conformational Changes Preceding Amyloid-fibril Formation of Amyloid-beta and Stefin B; Parallels in pH Dependence, Current Medicinal Chemistry 2002; 9 (19) . https://dx.doi.org/10.2174/0929867023369097
DOI https://dx.doi.org/10.2174/0929867023369097 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Graphical Abstracts
Current Pharmaceutical Analysis Meet Our Editorial Board Member
Combinatorial Chemistry & High Throughput Screening Quantum Dots as Promising Theranostic Tools Against Amyloidosis: A Review
Protein & Peptide Letters CGRP Receptor Antagonism and Migraine Therapy
Current Protein & Peptide Science Microglial Store-operated Calcium Signaling in Health and in Alzheimer’s Disease
Current Alzheimer Research Editorial (Thematic Issue:Classic and New Agents to the Treatment of Affective Disorders: Some Concerns and Perspectives
Current Psychopharmacology The Role of Matrix Metalloproteinases in Essential Hypertension
Current Topics in Medicinal Chemistry MicroRNA-155 Regulates Inflammatory Response in Ischemic Cerebral Tissues through Autophagy
Current Neurovascular Research Hydrolases in Organic Chemistry. Recent Achievements in the Synthesis of Pharmaceuticals
Current Organic Chemistry Genetic and Pharmacogenetic Aspects of Alcohol-Dependence
Current Pharmacogenomics Effects of Resveratrol and Other Polyphenols on the Most Common Brain Age-Related Diseases
Current Medicinal Chemistry Commentary: (Research Highlights: “MiRNAcles” in Brain)
CNS & Neurological Disorders - Drug Targets Development of New H1 Antihistamines: The Importance of Pharmacokinetics in the Evaluation of Safe and Therapeutically Effective Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Amine Oxidase Inhibitors and Development of Neuroprotective Drugs
Current Neuropharmacology A More Radical Solution
Reviews on Recent Clinical Trials Evaluation of Self Monitoring of Blood Glucose in Non-Insulin-Treated Diabetic Patients by Randomized Controlled Trials: Little Bang for the Buck
Reviews on Recent Clinical Trials Vasorelaxation Caused by Cannabinoids: Mechanisms in Different Vascular Beds
Current Vascular Pharmacology Cross-Cultural Comparison of Mild Cognitive Impairment between China and USA
Current Alzheimer Research Analysis of Copy Number Variation in Alzheimer’s Disease: The NIALOAD/ NCRAD Family Study
Current Alzheimer Research Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design